Subject Index consent decree, 48 direct-to-consumer advertising (DTC), 109, 121, 130 discretionary authority of, 66 Division of Drug Marketing, Advertising and Communications (DDMAC), 63 Drug Amendments (1962), 42, 46, 52 "FDA approved", 59 first legal challenge to, 50 Food, Drug & Cosmetic Act (FD&C Act), 43, 53, 55 Modernization Act of 1997 (FDAMA), 60-61, 86, 92, 123,283-284 prescription drug deregulation, 126 Rufen DTC decision, 122 use of digital technology, 105 warning letters, 128 see also direct-to-consumer advertising (DTC) Framework for Environmental Ilealth Risk Management, 3 7 Frank J. Corbett, Inc., 289 Frohlich, Ludwig Wilhelm (Bill), 68, 71-72, 289 Frohlich Agency, 72 full disclosure, 56-57 Funding First, 27 Genetic Information NonDiscrimination Act (GINA), 35-36 genomics, 25-27, 30-31, 33, 34 Gerbic, Snell/Weisheimer & Associates, 87 Gerson, Irwin C., 290 GFIBM Healthworld, 290 Gideon, David, 291 Girard, Audrey, 292 Girgenti, Hughes, Butler & McDowell, 87 Girgenti, Steve, 87 Glaxo, 123 Gleevec, 33 Glenn, Edward, 76 global brand book, 77 globalization agency structures and, 68-71 branded advertising and, 77, 78 campaign coordination for, 75-78, 90 of Euro RSCG Life Worldwide, 79 of pharmaceutical industry, 69-70 Grey Healthcare Group, 79, 87 Gross Townsend Frank IIoffman, 87, 291 Group DCA, 116 GSK/Bayer, 88, 131 Hamill, Dorothy, 132 Harcourt General, 142 Harry C. Phibbs Advertising, 290 Havas, 87, 112 Hayes, Arthur Hull, Jr., 122 Haymarket, 141, 142 Health and Human Services (HHS), 43 health information, see consumer health information Health Insurance Portability and Accountability Act of 1996 (HIPPA), 33 HealthSTAR Communications, 292 Healthworld, initial public offering (IPO) of, 87-88 "heavy writing" physicians, 138 help-seeking advertisements, see disease awareness advertisements Hennessey, Matthew J., 68, 73-74, 74-75, 289 Herceptin, 33 HMC, 291 Hoechst, international campaigns, 75 Hoffman, Ronnie, 291 Holliday, Linda, 110 hormone replacement, 132 Hughes, Frank, 290 human element of presentations, 104 Human Genome Project, 25-27, 34 Huntsworth Health, 79 Hutton, Lauren, 132 hydrocortisone, 126 ibuprofen (Rufen), 121-122 iFrontier, 112 IMC2, 112 Imodium, 78-79 InChord, 87 Indigenus, 79 in-doctor-office advertising, 91 initial public offering (IPO), 87-88 in-person advertising, 141-142 in-pharmacy advertising, 91 Institute of Medicine (IOM), 32, 51 institutional review boards (IRBS), 33 Intellisphere, 142 interactive process, 84, 117, 145 Intercon, 71-73 Intermune (Actimune), 49 internet advertising advantages of, 133 direct-to-consumer advertising (DTC), 91, 112-114, 132-133 effect on physician-to-patient relationship, 114 entrepreneurs in, 110-112 full disclosure and, 56-57 health information through, 109 manuscripts for, 102 by medical journals, 140-141 to physicians, 115-116 protocol development, 96 and rules for broadcast advertisements, 54, 56, 63 Interpublic, 87 InVentiv Health, 79, 87 IPG, 112 J. Walter Thompson, 76 Janssen Pharmaceutica (Belgium), 79 Jarvik, Robert, 132 J.B. Lippincott, 142 Jenner, Bruce, 132 Jobson Flealthcare Group, 142 John Wiley & Sons, 142 Jones, Dick, 77, 290 Journal Ad Review, 138 Journal of the American Medical Association (JAMA), 137 Juice, 88 Kallir, John, 289 Kallir Philips Ross (KPR), 78-79, 87, 289, 290, 291, 292 Kamp, John F., 51 Kane & Finkel, 88 Kefauver hearings, 137 Kessler, David, 121 Key Pharmaceuticals, 292 Kindle reader, 145-146 Kirchner, Joann E., 290 Klemtner, Paul, 289 Klemtner Advertising, 87, 291 KnowledgePoint360 Group, 143 Kos Pharmaceuticals, 292 Kramer, David, 110 LaBelle, Patti, 132 Ladd, Cheryl, 132 Lakeside Division of Merrill Dow, 123 Lally, John, 289 Lally, McFarland & Pantello, 86, 289, 290, 292 Lasker Charitable Trusts, 27 Lathian Health, 115-116 Lavey, Kenneth H., 289 Lavey Wolff Swift, 87, 289 layout, digital technology effect on, 102-103 Lebhar-Friedman, 142 Leo Labs (Nicorette), international campaigns, 75 Lesser, Larry, 72-73 Levitra, 131 298
RkJQdWJsaXNoZXIy NDMwNDAx